EU plans to limit what drugmakers tell public
Source: Agencies |
October 12, 2011, Wednesday
|
Print Edition
Print Edition
EUROPE will strictly limit the amount of information drugmakers can supply to the public on prescription-only medicines and retain a ban on advertising under proposed rules set out yesterday.
The latest proposals from the European Commission amend those made in 2008, following criticism that the original ideas went too far in loosening restrictions governing communications between pharmaceuticals companies and patients.
John Dalli, European commissioner for health and consumer policy, said the new proposals would "strengthen the control of authorized medicines."
The new proposals from the commission, the executive arm of the European Union, would allow information in only certain areas, such as information on the label and on packaging leaflets, information on prices and clinical trials, and instructions for use.
An earlier idea of letting drugmakers publish information about medicines on websites or in print - for example, in health supplements in newspapers - has been rejected under the new proposals, which state: "A publication in general print media will not be permitted."
The tough line may disappoint drugmakers wanting more leeway to provide information directly to consumers in Europe, which they argue is needed in part as a counterbalance to sometimes unreliable data provided on the Internet.
But the commission's new line was welcomed by the European Public Health Alliance, which represents healthcare professionals and patients, for keeping advertising at bay.
Monika Kosinska, the group's secretary general, said: "The previous proposal was just a disguised way of giving pharmaceutical companies enough flexibility to promote their products directly to the public in order to boost the sector's growth."
In fact, the European pharmaceutical industry had never asked for a green light for US-style direct-to-consumer advertising, which some company executives anyway now view as a costly mistake.
Such advertising of prescription drugs is permitted only in the US and New Zealand, and has been widely criticized by US consumer groups, especially in the wake of the 2004 withdrawal of Merck's heavily promoted painkiller Vioxx.
Instead, drugmakers in Europe would like to steer a middle course between full-on television adverts and zero communication.
The European Federation of Pharmaceutical Industries and Associations said: "Those citizens seeking information on their disease or therapy should be able to access it in both user-friendly formats and in their own language."
Consumer groups have resisted any loosening of restrictions, arguing that drugmakers cannot be trusted to provide unbiased information.
The European Consumers' Organization said the redrafting of the plans were a first tangible effect of the decision to move competence on pharmaceuticals policy from the commission's industry division to the directorate responsible for health.
The latest proposals from the European Commission amend those made in 2008, following criticism that the original ideas went too far in loosening restrictions governing communications between pharmaceuticals companies and patients.
John Dalli, European commissioner for health and consumer policy, said the new proposals would "strengthen the control of authorized medicines."
The new proposals from the commission, the executive arm of the European Union, would allow information in only certain areas, such as information on the label and on packaging leaflets, information on prices and clinical trials, and instructions for use.
An earlier idea of letting drugmakers publish information about medicines on websites or in print - for example, in health supplements in newspapers - has been rejected under the new proposals, which state: "A publication in general print media will not be permitted."
The tough line may disappoint drugmakers wanting more leeway to provide information directly to consumers in Europe, which they argue is needed in part as a counterbalance to sometimes unreliable data provided on the Internet.
But the commission's new line was welcomed by the European Public Health Alliance, which represents healthcare professionals and patients, for keeping advertising at bay.
Monika Kosinska, the group's secretary general, said: "The previous proposal was just a disguised way of giving pharmaceutical companies enough flexibility to promote their products directly to the public in order to boost the sector's growth."
In fact, the European pharmaceutical industry had never asked for a green light for US-style direct-to-consumer advertising, which some company executives anyway now view as a costly mistake.
Such advertising of prescription drugs is permitted only in the US and New Zealand, and has been widely criticized by US consumer groups, especially in the wake of the 2004 withdrawal of Merck's heavily promoted painkiller Vioxx.
Instead, drugmakers in Europe would like to steer a middle course between full-on television adverts and zero communication.
The European Federation of Pharmaceutical Industries and Associations said: "Those citizens seeking information on their disease or therapy should be able to access it in both user-friendly formats and in their own language."
Consumer groups have resisted any loosening of restrictions, arguing that drugmakers cannot be trusted to provide unbiased information.
The European Consumers' Organization said the redrafting of the plans were a first tangible effect of the decision to move competence on pharmaceuticals policy from the commission's industry division to the directorate responsible for health.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
